M
M S Ali
Researcher at University of Oxford
Publications - 12
Citations - 117
M S Ali is an academic researcher from University of Oxford. The author has contributed to research in topics: Kidney disease & Hypocalcaemia. The author has an hindex of 4, co-authored 12 publications receiving 87 citations. Previous affiliations of M S Ali include University of London.
Papers
More filters
Journal ArticleDOI
One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study.
Carlen Reyes,Cristian Tebé,D Martinez-Laguna,M S Ali,A Soria-Castro,C. Carbonell,Daniel Prieto-Alhambra,Daniel Prieto-Alhambra +7 more
TL;DR: A cohort study using a real-world population database to estimate the persistence of anti-osteoporosis drugs found that unadjusted 2-year persistence is suboptimal and both teriparatide and denosumab users had better 1- year persistence and only denosumsumab had 2- year better persistence compared to alendronate users.
Journal ArticleDOI
Real-world antidiabetic drug use and fracture risk in 12,277 patients with type 2 diabetes mellitus: a nested case-control study.
E Losada,Berta Soldevila,M S Ali,M S Ali,D Martinez-Laguna,D Martinez-Laguna,Xavier Nogués,Xavier Nogués,Manel Puig-Domingo,A Diez-Perez,A Diez-Perez,Didac Mauricio,Daniel Prieto-Alhambra,Daniel Prieto-Alhambra,Daniel Prieto-Alhambra +14 more
TL;DR: Insulin monotherapy was associated with an increased fracture risk compared to MTF monotherapy in T2DM patients, and sensitivity analyses suggest possible causality for insulin therapy but not for the MTF + SU combination association.
Journal ArticleDOI
Comparative cardiovascular safety of strontium ranelate and bisphosphonates: a multi-database study in 5 EU countries by the EU-ADR Alliance.
M S Ali,M S Ali,Klara Berencsi,Klara Berencsi,K Marinier,N Deltour,S Perez-Guthann,Lars Pedersen,P Rijnbeek,Francesco Lapi,Monica Simonetti,Carlen Reyes,J van der Lei,Miriam C. J. M. Sturkenboom,Daniel Prieto-Alhambra,Daniel Prieto-Alhambra +15 more
TL;DR: In patients without contraindications for SR, this work found no evidence of an increased risk of AMI but a 25–30% excess risk of VTE and a 35% extra risk of CVDeath with current vs past SR users, despite a reduction in risk in CVDeath in current vs current BP users.
Journal ArticleDOI
Impact of risk minimisation measures on the use of strontium ranelate in Europe: a multi-national cohort study in 5 EU countries by the EU-ADR alliance
Klara Berencsi,Klara Berencsi,A Sami,M S Ali,M S Ali,K Marinier,N Deltour,S. Perez-Gutthann,Lars Pedersen,P Rijnbeek,J van der Lei,Francesco Lapi,Monica Simonetti,Carlen Reyes,Miriam C. J. M. Sturkenboom,Daniel Prieto-Alhambra,Daniel Prieto-Alhambra +16 more
TL;DR: A substantial impact of the regulatory action to restrict use of SR in Europe is demonstrated: SR utilisation overall decreased strongly and the proportion of patients fulfilling the restricted indications, without contraindications, increased after the proposed RMMs.